



SYNTHESIS AND BIOLOGICAL ACTIVITY OF AZETIDINONE

Deepak Kumar¹, F.B.Bux¹, and Arun Singh²

¹P.G.Department of Chemistry, Govt. Geetanjali Girls College, Bhopal, India

²Joint Director, Rajya Siksha Kendra, Pustak Bhawan, B-Wing, Arera Hills, Bhopal, India

*E-mail: dr.arunsingh@rediffmail.com

ABSTRACT

2-(5-benzoyl-1H-benzo[d]imidazol-1-yl) acetohydrazide (1) undergoes facile condensation with aromatic aldehydes to afford the corresponding 2-(5-benzoyl-1H-benzo[d]imidazol-1-yl)-N'-arylideneacetohydrazide (2a-h) in good yield. Cyclocondensation of compounds (2a-h) with chloro acetyl chloride yields 2-(5-benzoyl-1H-benzo[d]imidazol-1-yl)-N-(3-chloro-2-aryl-4-oxoazetidin-1-yl)acetamide (3a-h). The structures of these compounds were established on basis of analytical and spectral data. The newly synthesized compounds were evaluated for their antibacterial and antifungal activities.

Keywords: acetohydrazide, azetidinone, antibacterial activity, spectral studies.

INTRODUCTION

Hydrazide and their heterocyclised products display diverse biological activity, including antibacterial, antifungicidal, analgesic, anti-inflammatory activity¹⁻¹⁵. These heterocyclic systems find wide use in medicine, agriculture and industry. One of the hydrazide i.e. 2-hydroxy benzoic acid hydrazide (salicylhydrazide) and their condensed products play a vital role in medicinal chemistry¹⁶⁻¹⁸. A large number of azetidinones containing β -lactam rings¹⁹⁻²³ are known to exhibit various biological activities like antibacterial, antifungal²⁴ and antibiotic²⁵ activities. More particularly and recently these types of compounds have been found in the treatment of T.B. and other chemotherapeutic diseases. Hence, it was thought of interest in merging of both azetidinone and benzimidazole hydrazide moieties may enhance the drug activity of compounds up to some extent or might possess some of the above mentioned biological activities. From this point of view, the objective of the present work is to prepare new derivatives of benzimidazole hydrazide containing an azetidinone moiety. Hence the present communication comprises the synthesis of 2-(5-benzoyl-1H-benzo[d]imidazol-1-yl)-N-(3-chloro-2-aryl-4-oxoazetidin-1-yl)acetamide. The research work is scanned in Scheme -1.

EXPERIMENTAL

Melting points were determined in open capillary tubes and are uncorrected. The IR spectra were recorded in KBr pellets on a Nicolet 400D spectrometer and ¹H NMR and ¹³C NMR spectra were recorded in DMSO with TMS as internal standard on a Bruker spectrometer at 400 MHz and 100 MHz, respectively. LC-MS of selected samples taken on LC-MSD-Trap-SL_01046.

Preparation of 2-(5-benzoyl-1H-benzo[d]imidazol-1-yl)-N'-arylideneacetohydrazide (2a-h)

An equimolecular mixture of 2-(5-benzoyl-1H-benzo[d]imidazol-1-yl)acetohydrazide(1), (0.01 mole) and the aromatic aldehydes (a-h) in ethanol (15ml) was refluxed on a water bath for 1-2 hrs. The solid separated was collected by filtration, dried and recrystallized from ethanol. The yields, melting points and other characterization data of these compounds are given in Table -1 and 2.

Preparation of 2-(5-benzoyl-1H-benzo[d]imidazol-1-yl)-N-(3-chloro-2-aryl-4-oxoazetidin-1-yl)acetamide (3a-h)

A mixture 2-(5-benzoyl-1H-benzo[d]imidazol-1-yl)-N'-arylideneacetohydrazide (2a-h) (0.002 mole) and triethyl amine (TEA) (0.004 mole) was dissolved in 1,4-dioxane (50 ml), cooled, and stirred. To this well-stirred cooled solution chloro acetyl chloride (0.004 mole) was added drop wise within a period of 30 minutes. The reaction mixture was then stirred for an additional 3 hours and left at room temperature for 48 hours. The resultant mixture was concentrated, cooled, poured into ice-cold water, and then air-dried.

The product thus obtained was purified by column chromatography over silica gel using 30% ethyl acetate: 70% benzene as eluent. Recrystallization from ether/n-hexane gave white powder of N – (3-chloro-2-oxo-4-aryl-azetid-1-yl)-2-hydroxy-benzamide (3a-h), which was obtained in 56-74% yield. All the compounds were characterized by analytical and spectral data (Table -3 & 4) of the compounds is assigned in Scheme -1.

Biological Screening

Antibacterial activities

Antibacterial activities of all the compounds were studied against gram-positive bacteria (*Staphylococcus aureus* and *Bacillus subtilis*) and gram-negative bacteria (*E.coli*, and *klebsiella promioe*) at a concentration of 50µg/ml by agar cup plate method. Methanol system was used as control in this method. Under similar condition using tetracycline as a standard for comparison carried out control experiment. The area of inhibition of zone measured in mm. Compound 3c, 3f and 3g were found more active against the above microbes. Other compounds found to be less or moderate active than tetracycline (Table -5).

Antifungal Activities

The fungicidal activity of all the compounds was studied at 1000 ppm concentration in vitro. Plant pathogenic organisms used were *Nigrospora Sp*, *Aspergillus Niger*, *Botrydepladia thiobromine*, and *Rhizopus nigricum*, *Fusarium oxyporium*. The antifungal activity of all the compounds (3a-h) was measured on each of these plant pathogenic strains on a potato dextrose agar (PDA) medium. Such a PDA medium contained potato 200gm, dextrose 20gm, agar 20gm and water one liter. Five days old cultures were employed. The compounds to be tested were suspended (1000ppm) in a PDA medium and autoclaved at 120° C for 15 min. at 15atm.pressure. These medium were poured into sterile Petri plates and the organisms were inoculated after cooling the Petri plates. The percentage inhibition for fungi was calculated after five days using the formula given below:

$$\text{Percentage of inhibition} = 100(X-Y) / X$$

Where, X = Area of colony in control plate

Y = Area of colony in test plate

The fungicidal activity displayed by various compounds (3a-h) is shown in Table - 6.

RESULTS AND DISCUSSION


It was observed that 2-(5-benzoyl-1H-benzo[d]imidazol-1-yl)acetohydrazide (1) on condensation with aromatic aldehydes to yield 2-(5-benzoyl-1H-benzo[d]imidazol-1-yl)-N'-arylideneacetohydrazide (2a-h). The structures of (2a-h) were confirmed by elemental analysis and IR spectra showing absorption band at 1628-1645(C=N), 3020-3080 cm⁻¹ (C-H, of Ar.), 1720-1750 cm⁻¹ (-CO), 2815-2850 cm⁻¹ (-OCH₃), 3450-3485cm⁻¹ (-OH), 2950, 1370 cm⁻¹ (-CH₃). The C, H, N analysis and ¹H NMR data of all compounds are presented in Table -1 and 2.

The cyclocondensation of (2a-h) with chloroacetylchloride resulted in formation of 2-(5-benzoyl-1H-benzo[d]imidazol-1-yl)-N-(3-chloro-2-aryl-4-oxoazetid-1-yl) acetamide (3a-h). The structures assigned to (3a-h) were supported by the elemental analysis and IR spectra showing absorption bands at 1750-1760 (C=O of monocyclic β-lactam), 3035-3090 cm⁻¹ (C-H, of Ar.), 3450-3550 cm⁻¹ (-OH), 2820-2850 cm⁻¹ (-OCH₃), 2950, 1370 cm⁻¹ (-CH₃). The C, H, N analysis and ¹H-NMR data of all compounds are presented in Table -3 and 4

The examination of data reveals that the elemental contents are consistence with the predicted structure shown in scheme -1. The IR data also direct for assignment of the predicted structure. The final structure of all compounds is confirmed by LC-MS data of selected samples. The LC-MS of samples 3b and 3e give the molecular ion peak (m/z) at 490 and 474 respectively. These values are corresponds to their molecular weight.

ACKNOWLEDGEMENTS

The authors are thankful to authorities of P.G. Department of Chemistry, Govt. Geetanjali Girls College Bhopal, India and Rajya Siksha Kendra, Pustak Bhawan, Bhopal, India for providing basic facilities for the present work.



Scheme - 1

Where, R = (a) C₆H₅ (b) 4-OCH₃-C₆H₄ (c) 4-OH-C₆H₄
(d) 2-OH-C₆H₄ (e) 4-CH₃-C₆H₄ (f) 3,4-CH₂O₂-C₆H₄
(g) 4-OH-3-OCH₃-C₆H₃ (h) 3,4-C₂H₅-C₆H₄

Table-1: Analytical Data and elemental analysis of compounds (2a-h)

Compd.	Molecular formula (Mol. wt.)	Yield	M.P. °C	Elemental Analysis					
				%C		%H		%N	
				Found	Calcd.	Found	Calcd.	Found	Calcd.
2a	C ₂₃ H ₂₈ N ₄ O ₂ (382)	88	238	72.1	72.25	4.7	4.71	14.6	14.65
2b	C ₂₄ H ₂₀ N ₄ O ₃ (412)	81	243	69.9	69.90	4.8	4.85	13.5	13.59

2c	C ₂₃ H ₁₈ N ₄ O ₃ (398)	78	240	69.2	69.34	4.5	4.52	13.9	14.07
2d	C ₂₃ H ₁₈ N ₄ O ₃ (398)	84	237	69.3	69.34	4.5	4.52	14.0	14.07
2e	C ₂₄ H ₂₀ N ₄ O ₂ (396)	80	242	72.6	72.72	4.9	5.05	14.0	14.14
2f	C ₂₄ H ₁₈ N ₄ O ₄ (426)	82	246	67.5	67.60	4.1	4.22	13.1	13.14
2g	C ₂₄ H ₂₀ N ₄ O ₄ (328)	79	248	67.2	67.28	4.6	4.67	12.9	13.08
2h	C ₂₇ H ₂₆ N ₄ O ₂ (438)	76	259	73.9	73.97	5.9	5.93	12.7	12.78

Table-2: Spectral data of compounds (2a-h)

¹ H NMR (δ, ppm)								
Compd.	Ar-H	-CONH	-N=CH	-CH ₃	-OCH ₃	-OH	-OC ₂ H ₅	-OCH ₂ O- cyclic
2a	6.5–7.9 (m, 14H)	11.80(s)	8.4(s)	-	-	-	-	-
2b	6.5–7.9 (m, 13H)	11.80(s)	8.4(s)	-	3.9(s)	-	-	-
2c	6.5–7.9 (m, 13H)	11.80(s)	8.4(s)	-	-	11.20(s)	-	-
2d	6.5–7.9 (m, 13H)	11.80(s)	8.8(s)	-	-	11.20(s)	-	-
2e	6.5–7.9 (m, 13H)	11.80(s)	8.4(s)	2.4(s)	-	-	-	-
2f	6.5–7.9 (m, 12H)	11.80(s)	8.4(s)	-	-	-	-	6.09 2H (s)
2g	6.5–7.9 (m, 12H)	11.80(s)	8.4(s)	-	3.9(s)	11.20(s)	-	-
2h	6.5–7.9 (m, 12H)	11.80(s)	8.4(s)	-	-	-	4.0, 4H, (q.) (CH ₂) 1.33, 6H, (t) (CH ₃)	-

Table-3: Analytical data and elemental analysis of Compounds (3a-h)

Compd.	Molecular formula (Mol.wt.)	Yield	M.P. °C	Elemental Analysis					
				%C		%H		%N	
				Found	Calcd.	Found	Calcd.	Found	Calcd.
3a	C ₂₅ H ₁₉ N ₄ O ₃ Cl (458.50)	62	242	65.4	65.43	4.1	4.14	12.2	12.21
3b	C ₂₆ H ₂₁ N ₄ O ₄ Cl (488.50)	58	254	63.8	63.86	4.2	4.29	11.4	11.46
3c	C ₂₅ H ₁₉ N ₄ O ₄ Cl (474.50)	57	246	63.2	63.22	3.9	4.00	11.7	11.80
3d	C ₂₅ H ₁₉ N ₄ O ₄ Cl	56	245	63.2	63.22	3.9	4.00	11.8	11.80

	(474.50)								
3e	C ₂₆ H ₂₁ N ₄ O ₃ Cl (472.50)	49	247	66.0	66.03	4.4	4.44	11.8	11.85
3f	C ₂₆ H ₁₉ N ₄ O ₅ Cl (502.50)	51	253	62.0	62.08	3.7	3.78	11.0	11.14
3g	C ₂₆ H ₂₁ N ₄ O ₅ Cl (504.50)	55	254	61.8	61.84	4.0	4.16	10.9	11.10
3h	C ₂₉ H ₂₇ N ₄ O ₃ Cl (514.50)	46	264	67.6	67.63	5.2	5.24	10.8	10.88

Table-4: Spectral data of compounds (3a-h)

¹ H NMR (δ, ppm)									
Compd.	C ₂ -H	C ₃ -H	Ar-H	-CH ₃	-OCH ₃	-OH	-OC ₂ H ₅	-CONH	-OCH ₂ O-cyclic
3a	5.0 (d, 1H)	5.5 (d, 1H)	6.9-7.9 (m, 14H)	-	-	-		7.8(s)	-
3b	5.0 (d, 1H)	5.5 (d, 1H)	6.9-7.9 (m, 13H)	-	3.9(s)	-		7.8(s)	-
3c	5.0 (d, 1H)	5.5 (d, 1H)	6.9-7.9 (m, 13H)	-	-	11.20(s)		7.8(s)	-
3d	5.0 (d, 1H)	5.5 (d, 1H)	6.9-7.9 (m, 13H)	-	-	11.20(s)		7.8(s)	-
3e	5.0 (d, 1H)	5.5 (d, 1H)	6.9-7.9 (m, 13H)	2.4(s)	-	-	-	7.8(s)	-
3f	5.0 (d, 1H)	5.5 (d, 1H)	6.9-7.9 (m, 12H)	-	-	-	-	7.8(s)	6.09 2H (s)
3g	5.0 (d, 1H)	5.5 (d, 1H)	6.9-7.9 (m, 12H)	-	3.9(s)	11.20(s)	-	7.8(s)	-
3h	5.0 (d, 1H)	5.5 (d, 1H)	6.9-7.9 (m, 12H)	-	-	-	4.0, 4H,(q) (CH ₂)1.33, 6H,(t) (CH ₃)	7.8(s)	-

REFERENCES

1. M. R. Shiradkar, K. K. Murahari, H. R. Gangadasu, T. Suresh, C. C. Kalyan, D. Panchal, R. Kaur, P. Burange, J. Ghogare, V. Mokale, M. Raut, *Bioorg. Med. Chem.*, **15**, 3997(2007).
2. Y. Janin, *Bioorg. Med. Chem.*, **15**, 2479(2007)
3. E. Gursoy, N. Guzeldemirci-Ulusoy, *Eur. J. Med. Chem.*, **42**, 320(2007).
4. M. R. Rao, K. Hart, N. Devanna and K. B. Chandrasekhar, *Asian J. Chem.*, **20**, 1402 (2008).
5. K. B. Kaymakcioglu, E. E. Oruc, S. Unsalan, F. Kandemirli, N. Shvets, S. Rollas, D. Anatholy, *Eur. J. Med. Chem.*, **41**, 1253(2006).
6. R. Kalsi, M. Shrimali, T. N. Bhalla, J. P. Barthwal, *Indian J. Pharm. Sci.*, **41**, 353 (2006).
7. S. Gemma, G. Kukreja, C. Fattorusso, M. Persico, M. Romano, M. Altarelli, L. Savini, G. Campiani, E. Fattorusso, N. Basilico, *Bioorg. Med. Chem. Lett.*, **16**, 5384(2006).
8. D. Sriram, P. Yogeewari, K. Madhu, *Bioorg. Med. Chem. Lett.*, **15**, 4502(2005).
9. A. Nayyar, R. Jain, *Curr. Med. Chem.*, **12**, 1873(2005).
10. R. M. Fikry, N. A. Ismael, A. A. El-Bahnasawy, A. A. Sayed El-Ahl., *Phos. Sulf and Silicon.*, **179**, 1227(2004).
11. A. Walcourt, M. Loyevsky, D. B. Lovejoy, V. R. Gordeuk, D. R. Richardson, *Int. J. Biochem. Cell Biol.*, **36**, 401(2004).
12. M. G. Mamolo, V. Falagiani, D. Zampieri, L. Vio, E. Banfi, G. Scialino, *Farmaco*, **58**, 631(2003).
13. N. Terzioglu, A. Gursoy, *Eur. J. Med. Chem.*, **38**, 781(2003).
14. S. G. Kucukguzel, E. E. Oruc, S. Rollas, F. Sahin, A. Ozbek, *Eur. J. Med. Chem.*, **37**, 197(2002).
15. S. Rollas, N. Gulerman, Erdeniz, H., *Farmaco*, **57**, 171 (2002).

16. L. Q. Al- Mawsawi, R. Dayam, L. Taheri, M. Witvrouw, Z. Debyser, N. Neamati, *Bioorg Med. Chem. Lett.*, **17** (23), 6472(2007).
17. C. Plasencia, R. Daym, Q. Wang, J. Pinski, T. R. Jr. Burke, D. I. Quinn, and N. Neamati, *Mol. Cancer ther.*, **4** (7) 1105-1113 (2005).
18. H. Zhao, N. Neamati, S. Sunder, H. Hong, S. Wang, G.W. Milne, Y. Pommier, T. R. Jr. Burke, *J. Med. Chem.*, **40** (6) 937(1997)
19. H. T. Clarke, J. R. Johnson, R. Robinson, The chemistry of penicillin, Princeton Uni. Press, Princeton. 1949.
20. H. S. Patel, H. J. Mistry, H. D. Desai, *Oriental J. Chem.*, **19**(1), 187(2003).
21. H. S. Patel, H. J. Mistry, Phosphorous, *Sulfur and Silicon*, **179**, 1085(2004).
22. H. S. Patel, V. K. Patel, *Ind. J. Heterocyclic Chem.*, **12**, 253(2003).
23. K. R. Desai, Bhanvesh Naik, *Ind.J.Chem.*, **45**(B), 267(2006).
24. V. V. Mulwad, B. P. Choudhari, *Indian J. Heterocyclic Chem.*, **12**, 197(2003).
25. K. Akiba, M. Wada, *Chem. Abstr.*, 111, 96964b (1989).

Table-5: Antibacterial Activities of Compounds (3a-h)

Compou	Gram +Ve		Gram -Ve	
	<i>Bacillus subtilis</i>	<i>Staphylococcus aureus</i>	<i>Klebsiella promioe</i>	<i>E.col</i>
3a	58	62	53	68
3b	63	63	65	57
3c	72	68	56	71
3d	62	59	63	62
3e	53	56	67	68
3f	74	72	60	64
3g	68	73	64	62
3h	66	70	46	62
Tetracylie	78	66	85	76

Table-6: Antifungal Activities of Compounds (3a-h)

Compounds	Zone of Inhibition at 1000 ppm (%)				
	<i>Aspergillus Niger</i>	<i>Botrydepladia Thiobromine</i>	<i>Fusarium oxyporium</i>	<i>Nigrospora Sp.</i>	<i>Rhizopus Nigricum</i>
3a	62	63	70	62	52
3b	58	64	68	61	67
3c	60	67	71	58	62
3d	49	65	66	67	74
3e	66	65	62	62	71
3f	55	66	65	66	62
3g	61	73	60	59	56
3h	67	71	67	66	72

(Received: 13 August 2010)

Accepted: 9 September 2010

RJC-620)

Adopt **GREEN CHEMISTRY**
Save Our Planet.
We publish papers of Green Chemistry on priority.